Roles of Autocrine TGF-β Receptor and Smad Signaling in Adipocyte Differentiation

Lisa Choy,*‡ Jeremy Skillington,*ʻ and Rik Derynck*†

*Department of Growth and Development, †Department of Anatomy, Programs in Cell Biology and Developmental Biology, University of California at San Francisco, San Francisco, California 94143-0640

Abstract. TGF-β inhibits adipocyte differentiation, yet is expressed by adipocytes. The function of TGF-β in adipogenesis, and its mechanism of action, is unknown. To address the role of TGF-β signaling in adipocyte differentiation, we characterized the expression of the TGF-β receptors, and the Smads which transmit or inhibit TGF-β signals, during adipogenesis in 3T3-F442A cells. We found that the cell-surface availability of TGF-β receptors strongly decreases as adipogenesis proceeds whereas mRNA levels for Smads 2, 3, and 4 were unchanged during differentiation, mRNA levels for Smads 6 and 7, which are known to inhibit TGF-β responses, decreased severely. Dominant negative interference with TGF-β receptor signaling, by stably expressing a truncated type I TGF-β receptor, enhanced differentiation and decreased growth. Stable overexpression of Smad2 or Smad3 inhibited differentiation and dominant negative inhibition of Smad3 function, but not Smad2 function, enhanced adipogenesis. Increased Smad6 and Smad7 levels blocked differentiation and enhanced TGF-β-induced responses. The inhibitory effect of Smad7 on adipocyte differentiation and its cooperation with TGF-β was associated with the C-domain of Smad7. Our results indicate that endogenous TGF-β signaling regulates the rate of adipogenesis, and that Smad2 and Smad3 have distinct functions in this endogenous control of differentiation. Smad6 and Smad7 act as negative regulators of adipogenesis and, even though known to inhibit TGF-β responses, enhance the effects of TGF-β on these cells.

Key words: inhibitory Smads • PPARγ • C/EBP • 3T3-F442A • retroviral vectors

Introduction

TGF-β regulates the differentiation program of a variety of cell types (for review see Derynck and Choy, 1998), including mesenchymal cells. For example, myogenesis is inhibited or stimulated by TGF-β depending on the cell type and the culture conditions. The addition of TGF-β generally inhibits myoblast differentiation (Massagué et al., 1986; Olson et al., 1986), but stimulates differentiation of embryonic myoblasts (Slager et al., 1993), whereas inhibition of type II TGF-β receptor signaling in C2C12 myoblasts blocks myogenic differentiation (Filvaroff et al., 1994). These data suggest that TGF-β signaling is required and provides competence for the early stages of myogenic differentiation, but inhibits later stages in the differentiation process. Such a model may also explain the many findings on stimulatory and inhibitory effects of TGF-β on chondrocyte and osteoblast differentiation, which likewise depend on culture conditions and the differentiation state of the cells (Kulyk et al., 1989; Ballock et al., 1993; Centrella et al., 1994). These dynamic responses of muscle and bone cells to TGF-β may relate to changes in receptor levels and ratios during differentiation (Hu and Olson, 1990; Centrella et al., 1995), and may highlight the complexity of differentiation responses of mesenchymal cells to TGF-β.

While the effects of TGF-β signaling on muscle, bone, and cartilage cell differentiation are well studied, little is known about how TGF-β regulates adipocyte differentiation. Furthermore, the mechanism by which TGF-β stimulates proliferation of mesenchymal cells (Sporn et al., 1986), including preadipocytes (Jeoung et al., 1995), is also poorly understood. It is known that TGF-β inhibits adipose differentiation of preadipocyte cell lines and primary cultures (Ignotz and Massagué, 1985; Sparks and Scott, 1986; Torti et al., 1989; Petruschke et al., 1994). In some preadipocyte cell lines, TGF-β must be administered before, or concomitant with, the induction of differentiation, after which the cells are refractory to TGF-β and do not revert to the undifferentiated state (Ignotz and Massagué, 1985; Sparks et al., 1992). However, TGF-β treatment can, in other cells, reverse the adipocyte phenotype (Torti et
TGF-β also blocks adipogenesis in vivo. Transgenic overexpression of TGF-β1 in adipose tissue severely reduces both white and brown adipose tissue masses, and results in the failure of adipocytes to differentiate (Clouthier et al., 1997). In spite of its ability to inhibit adipocyte differentiation, TGF-β1 is expressed in cultured adipocytes (Sparks et al., 1993; Bortell et al., 1994), and adipose tissue (Samad et al., 1997). The relative increase of TGF-β1 levels in obese adipose tissue may result from increased expression of tumor necrosis factor α (Samad et al., 1999), another cytokine that, like TGF-β, inhibits adipocyte differentiation in vitro (Torti et al., 1985).

Collectively, these observations suggest a role for endogenous TGF-β in the development and function of adipose tissue. However, very little is known about the signaling mechanisms that lead to the differentiation responses to TGF-β. TGF-β family factors bind to a heteromeric cell-surface complex of two type II and two type I receptors (for reviews see Derynck and Feng, 1997; Heldin et al., 1997; Massagué, 1998). Both receptor types are transmembrane serine/threonine kinases, and ligand binding induces phosphorylation and activation of the type I receptors by the type II receptor kinases. TGF-β signaling is transduced through a complex series of downstream signaling molecules, which lead to activation of various transcription factors, including members of the SMAD family (Massagué, 1998). In adipose tissue, TGF-β signaling is thought to regulate the expression of genes involved in fat cell differentiation and function (Chen et al., 1999; Sun et al., 1999). The TGF-β receptor, along with its common partner Smad4 and the SMAD4-binding proteins, Smad6 and Smad7, have distinct roles in the adipogenic differentiation process (Torti et al., 1985).

Materials and Methods

Construction of Expression Plasmids

Construction of Expression Plasmids

E expression plasmids for the cytoplasmically truncated, dominant negative version of the type II TGF-β receptor (dnTβRII; Chen et al., 1993) or for Smad2 or Smad3 (Zhang et al., 1998) were described previously. The coding sequence for the Smad2ASSM5 mutant was generated by replacing the COOH-terminal sequence of Smad2 at the BamHI site, which is located 33 bp upstream of the stop codon, and replacing it with annealed oligonucleotides encoding the identical DNA sequence but lacking the last four codons. The CdNA for mouse Smad3ASSV5 was created by PCR amplification of the human Smad3 sequence without the last four codons, and was obtained from Y. Zhang (University of California, San Francisco, San Francisco, CA). The CDNA for mouse Smad6 and mouse Smad7 were obtained from K. Miyazono (The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan) and P. ten Dijke (Ludwig Institute for Cancer Research, Uppsala, Sweden), respectively. Mutant versions of mouse Smad7 containing a 19-amino acid deletion at the COOH terminus (Smad7ΔC) or consisting only of the C-domain, amino acids 204–426 (Smad7C), were obtained from P. ten Dijke.

To study adipocyte differentiation, we altered TGF-β signaling in adipocytes by overexpressing wild-type or dominant negative mutants of Smad2 or Smad3, wild-type Smad6 or Smad7, or Smad7 mutants. The consequences of these changes in signaling on adipogenesis strongly suggest that TGF-β responsiveness regulates adipocyte differentiation, and that Smad2 and Smad3, and the inhibitory Smad6 and 7, have distinct roles in the adipogenic differentiation process.

Cell Culture and Generation of Stable Cell Lines

The preadipocyte cell line 3T3-F442A (Green and Kehinde, 1976) was obtained from H. Green (Harvard Medical School, Boston, MA). The cells were grown and differentiated as described (Dobson et al., 1987), except that incubators were set at 5% rather than 10% CO₂. To study differentiation in the presence of TGF-β, TGF-β was added to the medium 2 d before confluence, and again at every medium change (three times per week). The ecotropic retroviral packaging cell line Phoenix E was obtained from G. Nolan (Stanford University, Stanford, CA), and maintained in DME with 3 μg/ml glucose (Cellgro), 10% FBS (HyClone Laboratories Inc.), 10 μM linoleic acid, and 10 μg/ml streptomycin.

To generate retroviruses, Phoenix E cells were plated at 2.7 × 10⁵ cells/60-mm tissue culture dish 24 h before transfection. Transfection was done using the calcium phosphate procedure (Graham and van der Born, 1973). The neomycin resistance gene cassette was inserted into the LNCX vector, which allows selection in the neomycin derivative G418 (Muller and Rossman, 1989). Smad2 and Smad3 and their dominant negative mutants were expressed from a new derivative of LNCX, which we named LPXC, and allows for selection in puromycin instead of G418. This plasmid was made by replacing the neo gene of LNCX with the puromycin resistance gene from pBabeuro (Morgenstern and Land, 1990). The coding regions for NH₂-terminally Flag-tagged Smad2, Smad2ASSSM5, Smad3, and Smad3ASSV5 were inserted into the H pal site of LPXC. The coding regions for NH₂-terminally Flag-tagged Smad6, Smad7ΔC, and Smad7C were cloned into the BamHI-XhoI sites of pBabeuro3, whereas the coding region of Smad7 were cloned into the BamHI-XhoI sites of pBabeuro3, as described previously (Zhang et al., 1998).
using the calcium phosphate method (Gorman et al., 1983), using 10 μg DNA per plate. 48 h after transfection, the conditioned medium containing recombinant retroviruses was collected and filtered through 0.22-μm sterilization filters. 1–1.3 ml of these supernatants were applied immediately to 3T3-F442A cells, which had been plated 18 h before infection at a density of 5.1 × 10^6 cells/well of 6-well dishes. Polybrene (Sigma Chemical Co.) was added to a final concentration of 8 μg/ml, and the supernatants were incubated with the cells for 3–5 h. Alternatively, cells overlaid with viral supernatants plus polybrene were centrifuged for 45 min at room temperature at 1,800 rpm in a Beckman GPR centrifuge. The medium was aspirated and replaced with fresh viral supernatant, and the procedure was repeated. A further infection, the cells were plated in fresh growth medium and cultured as usual. Selection with 1 mg/ml G418 (Life Technologies, Inc.) or 2 μg/ml puromycin (Calbiochem) was initiated 48 h after infection.

Assay of Cell Growth Rates

Cells were trypsinized, resuspended in growth medium without selective antibiotic, and 2 × 10^6 cells were plated per well of 24-well dishes. The cells were washed twice with PBS on the following day, and then overlaid with DMEM containing 0.5% BSA (Sigma Chemical Co.) either without or with the indicated concentrations of TGF-β. The next day, [3H]thymidine (2 Ci/mmol; NEN) was added to the medium at a concentration of 4 μCi/ml. Uptake of the label proceeded for 4–5 h. Cells were washed twice with PBS, fixed for 20 min with 10% TCA, washed twice with water, and solubilized for 20 min in 1 N NaOH. A equal volume of 1 N HCl was added, and the resulting lysate was subjected to liquid scintillation counting.

Analysis of Lipid Accumulation, RNA, and Protein

Neutral lipid accumulation was visualized by washing cell monolayers once with PBS, fixing for 15 min with buffered formalin, and staining them for 1 h in a freshly made solution containing four parts water mixed with six parts 0.5% Oil Red O (Sigma Chemical Co.) in isopropanol. Excess stain was removed, and the cells were washed several times with water.

RNA was isolated using the SV RNA isolation kit (Promega). 10 μg total RNA was denatured and electrophoresed in 1% formaldehyde gels, blotted to Biotrans nylon membranes (ICN), and hybridized to 32P-labeled cDNAs, as described previously (Aubusel et al., 1994). DNA probes were labeled to a specific activity of at least 10^6 cpm/μg with [γ32P]ATP (6,000 Ci/mmol; NEN) by the random priming method (Feinberg and Vogelstein, 1983). The cDNAs for C/EBPα, PPARγ, and adipin were obtained from B. Spiegelman (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA). The cDNAs for C/EBPβ and δ were provided by S. McKnight (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA). The cDNAs for TGF-RII and TGF-RI mRNA were assessed by cross-linking [125I]TGF-β to the cell surface, the availability of these receptors strongly decreased during differentiation. The total expression levels of the receptors could not be determined because of the low expression levels and limited quality of the available antibodies (data not shown). The strong decrease in cell-surface availability of the receptors during adipose differentiation, in contrast to the mRNA levels for TGF-RII and TGF-RI, indicates that the cells posttranscriptionally downregulate TGF-β binding as they differentiate.

Regulation of Smad Expression during Adipocyte Differentiation

Smads act as intracellular effectors of TGF-β signaling. Smad2 and Smad3 are activators of TGF-β responses, and form heteromeric complexes with the common mediator Smad4. In contrast, Smad6 and Smad7 block TGF-β responses. We assessed the mRNA expression of these Smads at different stages of adipose differentiation, both

Figure 1. TGF-β receptor expression during adipocyte differentiation of 3T3-F442A cells. (A) Northern analysis of TβRII and TβR1 mRNA expression on 2 μg of poly(A)+ RNA from preadipocytes (pread) or 8 d after confluent adipocytes (ad). Levels of C/EBPβ mRNA are shown as a loading control. (B) Cell-surface availability of TGF-β receptors, as assessed by chemical cross-linking to [125I]TGF-β, decreases during differentiation. TGF-β binding was assessed in confluent preadipocytes (pread) and at 1, 3, and 10 d after confluence. The approximate positions of type III (RIII), type II (RII), and type I (RI) receptors are indicated.
allowed to differentiate without added TGF-β. Northern analysis of Smad mRNA expression during differentiation (Fig. 2). Cells were allowed to differentiate without added TGF-β, or in the presence of 5 ng/ml TGF-β beginning at 2 d preconfluence, and RNA was harvested at the days indicated. 10 μg total RNA was blotted and sequentially hybridized to cDNA probes for Smad2, Smad3, Smad4, Smad6, and Smad7, and for PPARγ (as marker for adipogenic conversion), as indicated. Ethidium bromide staining of the gel (EtBr) is shown as a loading control. All autoradiograms were exposed for 24 h except for PPARγ, which was exposed for 8 h.

Figure 2. Northern analysis of Smad mRNA expression during differentiation and in response to TGF-β treatment. Cells were allowed to differentiate without added TGF-β, or in the presence of 5 ng/ml TGF-β beginning at 2 d preconfluence, and RNA was harvested at the days indicated. 10 μg total RNA was blotted and sequentially hybridized to cDNA probes for Smad2, Smad3, Smad4, Smad6, and Smad7, and for PPARγ (as marker for adipogenic conversion), as indicated. Ethidium bromide staining of the gel (EtBr) is shown as a loading control. All autoradiograms were exposed for 24 h except for PPARγ, which was exposed for 8 h.

in TGF-β-treated and untreated cells (Fig. 2). In these experiments, the TGF-β-treated cells failed to differentiate, as judged from the absence of lipid accumulation, although analysis of PPARγ mRNA expression indicated that differentiation was not entirely blocked, but strongly decreased and delayed. Thus, PPARγ expression increased with time in TGF-β-treated cells, but never achieved the expression level seen in untreated cells (Fig. 2). All five Smads were expressed at all stages of differentiation of these cells. The Smad2 or Smad4 mRNA levels were unaffected by the differentiation stage or by TGF-β, whereas Smad3 mRNA levels did not significantly change during differentiation, but were decreased by TGF-β. This TGF-β-induced repression decreased with the progression of adipose differentiation. Both Smad6 and Smad7 mRNAs decreased during differentiation, with Smad7 mRNA levels decreasing more abruptly than Smad6. In addition, TGF-β increased Smad7 expression, but did not have a significant effect on Smad6 mRNA levels. We were unable to clearly detect endogenous Smad proteins, most likely because of poor antibody quality and/or low protein abundance (data not shown). Collectively, our data show that all TGF-β Smads are expressed in 3T3-F442A cells, and that expression of the inhibitory Smads decreases during adipogenesis.

**Decreased TGF-β Receptor Signaling Results in Accelerated Adipogenesis**

Since the levels of cell-surface TGF-β receptors and inhibitory Smads decreased during adipocyte differentiation, we determined the role of endogenous TGF-β signaling and Smads in the growth and differentiation of these cells. We created cell lines, via retroviral transduction, which stably expressed individual components of the TGF-β signaling system. First, we attempted to generate cells that would stably overexpress wild-type TβRII, to counteract the differentiation-linked suppression of cell-surface TGF-β receptors. However, the virally expressed TβRII levels, while not decreased during differentiation as the endogenous receptors (data not shown), were too low to significantly change the overall receptor level or profile during differentiation. In contrast, we successfully generated cells that expressed a cytoplasmically truncated TβRII (dnTβRII), which acts as a dominant negative inhibitor of TGF-β signaling (Chen et al., 1993). Similar to what we observed for wild-type TβRII, the expression of dnTβRII was lower than the endogenous TβRII level. Whereas the dnTβRII protein could not be convincingly detected in metabolically labeled lysates (data not shown), it could be detected in undifferentiated and differentiated dnTβRII cells by cross-linking [125I]TGF-β to the cell-surface receptors (Fig. 3, A and B). The low dnTβRII levels, when compared with endogenous TβRII, suggested that the TGF-β response in the dnTβRII cells would only be partially inhibited.

Using these cells, we evaluated the effect of dnTβRII expression on adipose differentiation, and in parallel, tested the effect of TGF-β at 1 ng/ml, added 2 d before confluence and continuously present thereafter. At this dose, TGF-β confers incomplete inhibition of adipose conversion (Ignotz and Massagué, 1985; Choy, L., unpublished data), which should enable us to detect the effects of enhancement or inhibition of TGF-β signaling. By 8 d after confluence, the dnTβRII cells differentiated similarly to the parental cells in the absence of added TGF-β, but were partially resistant to the differentiation-inhibiting effect of TGF-β, as judged by neutral lipid staining (Fig. 4 A). Northern analysis of adipocyte differentiation markers

Figure 3. Expression of cytoplasmically truncated TβRII in stably infected preadipocytes (A) and adipocytes (B). Cell-surface availability of TGF-β receptors was assessed by binding and chemical cross-linking to [125I]TGF-β. The first two lanes of each panel contain samples of total lysates, whereas the last two lanes contain immunoprecipitations using anti-Flag antibody, which recognizes the Flag epitope tag of dnTβRII. Positions of TβRII (R1), TβRI (R1), and dnTβRII are indicated. Endogenous TβRI is coprecipitated with the dnTβRII, as expected. The mobility of the receptors was slightly different in total lysates versus immunoprecipitates because of differing salt conditions and/or the presence of IgG in the immunoprecipitates. Exposure times were identical for all panels.
was performed at various points during differentiation. We analyzed the expression of the five transcription factors that are known to play important roles in adipogenesis (Gréroire et al., 1998), C/EBPβ, C/EBPα, ADD-1, PPARγ, and C/EBPα, as well as the later markers aP2 and adipsin. This study indicated that, while the extent of differentiation of dnTβRII and control cells was similar at day 8 after confluence, the rate of differentiation of dnTβRII cells was enhanced when compared with the parental cells (Fig. 4 B). Thus, at day 3 after confluence, the mRNA levels for PPARγ, C/EBPα, aP2, and adipsin were significantly higher in dnTβRII cells than in control cells. In contrast, the mRNA levels of C/EBPβ, C/EBPα, and ADD-1, earlier markers of adipogenic differentiation, were similar in both cell lines. The increased mRNA levels for PPARγ, C/EBPα, aP2, and adipsin in dnTβRII cells are consistent with the ability of TGF-β to repress expression of these markers (Torti et al., 1989; Stephens et al., 1993; Xing et al., 1997) and suggest that endogenous TGF-β responsiveness regulates adipocyte differentiation. Accordingly, TGF-β-treated control cells at day 8 after confluence exhibited decreased expression of these four later markers, as well as ADD-1, although they expressed C/EBPβ and C/EBPα at similar levels as untreated control cells. Consistent with their impaired TGF-β responsiveness, TGF-β-treated dnTβRII cells showed only slight inhibition of the later differentiation markers.

TGF-β stimulates the proliferation of many types of mesenchymal cells, including 3T3-F442A preadipocytes (Jeoung et al., 1995). Therefore, we compared the growth rates of control preadipocyte cells and dnTβRII cells, in the absence or presence of added TGF-β. Growth was assayed by [3H]thymidine incorporation, a measure of DNA synthesis, under subconfluent conditions. In the absence of added TGF-β, the growth rate ofdnTβRII cells was 25–30% lower than that of the control cells, and in the presence of TGF-β, the mitogenic response of dnTβRII cells was only half of that of the control cells (Fig. 4 C). These results show that, despite the modest dnTβRII expression level, the TGF-β response was significantly affected. Collectively, these results show that the TGF-β responsiveness regulates adipocyte differentiation in culture, and that impaired TGF-β responsiveness results in accelerated differentiation and slower growth.

**Smad2 and Smad3 Differentially Regulate Adipogenesis and Cell Proliferation**

To characterize the roles of Smad2 and Smad3 in adipocyte differentiation of 3T3-F442A cells, we generated two pairs of cell lines. One pair overexpressed wild-type Smad2 or Smad3, while the complementary pair expressed mutant versions of Smad2 (Smad2ΔSSM) or Smad3 (Smad3ΔSSV). These mutants lacked the last four amino acids, including the COOH-terminal serines, and, thus, cannot be phosphorylated by the activated TβRI. Similarly to the 3SA derivatives of Smad2 and Smad3, in which the last three serines are mutated to alanine (Macias-Silva et al., 1996; Liu et al., 1997), overexpression of Smad2ΔSSM or Smad3ΔSSV resulted in dominant negative interference of signaling by Smad2 or Smad3 in transfection/reporter assays (data not shown). Expression of wild-type and mutant Smad2 or Smad3 proteins could be readily detected in the stable cell populations (Fig. 5 A). While we were unable to clearly detect endogenous Smad proteins, the viral transcripts were expressed at a >100-fold higher level than the endogenous Smad2 and Smad3 mRNA's (data not shown).

We tested the abilities of these stable cell lines to undergo adipocyte differentiation and the ability of TGF-β to inhibit their differentiation. Expression of either Smad2 or Smad2ΔSSM inhibited lipid accumulation, although the effect of Smad2ΔSSM was weaker than Smad2 (Fig. 5 B). Enhanced Smad3 expression resulted in a stronger inhibitory effect than Smad2 overexpression, while cells expressing Smad3ΔSSV differentiated similarly to vector control cells (Fig. 5 B). In the presence of 1 ng/ml TGF-β, Smad2 or Smad3 expression both significantly augmented...
The differentiation-inhibiting effect of TGF-β (Fig. 5 C). However, the effect of Smad3 was stronger than Smad2; no lipid-accumulating cells were found in the Smad3-expressing cultures, whereas a few could be seen among the cells overexpressing Smad2. Cells expressing Smad3ΔSSVS differentiated to a much greater extent than control cells in the presence of TGF-β, demonstrating that this Smad3 mutant blocked the differentiation-inhibitory ef-
fect of TGF-β. In contrast, expression of Smad2ΔSSMS did not block this effect of TGF-β, and slightly enhanced the inhibitory effect of TGF-β (Fig. 5 C).

The effect of these Smads on lipid accumulation was reflected in the expression pattern of adipocyte differentiation mRNAs (Fig. 6 A). The induction of PPARγ, ADD-1, C/EBPα, aP2, and adipin was strongly reduced in cells with increased Smad3 expression, whereas the differentiation-dependent suppression of C/EBPα was abrogated. Smad2 or Smad2ΔSSMS expression resulted in only a slight decrease in the differentiation-dependent induction of the differentiation markers, whereas Smad3ΔSSVS expression did not significantly alter their expression. In the presence of TGF-β, the Smad3ΔSSVS cells expressed PPARγ, C/EBPα, aP2, and adipin at higher levels than in TGF-β-treated control cells, suggesting that impaired Smad3 signaling suppresses the responsiveness to TGF-β.

In contrast, Smad2ΔSSMS expression enhanced the TGF-β-mediated suppression of these differentiation markers, although to a lesser extent than in cells overexpressing Smad2 or Smad3.

We also measured the effect of overexpression of Smad2 or Smad3 or their dominant negative mutants on the growth rate (Fig. 6 B). Expression of Smad2 or Smad2ΔSSMS had little if any effect on cell proliferation or its stimulation by TGF-β. In contrast, Smad3 overexpression stimulated cell growth about threefold, both in the presence or absence of TGF-β. Expression of Smad3ΔSSVS inhibited the growth rate in the presence of TGF-β, and was ~30% less than the vector alone (Fig. 6 B).

Finally, we evaluated the effect of TGF-β on the morphology of these cell lines (Fig. 7). A dipogenic conversion
of control cells in the absence of TGF-β resulted in rounding, accumulation of lipid droplets, and a consequent enlargement of the cells, whereas nearby cells that had not yet undergone differentiation maintained a fibroblastic appearance (Fig. 7 A). TGF-β treatment prevented cell rounding and lipid accumulation and conferred a more densely packed, spindly morphology to the cells (Fig. 7 B). Increased expression of Smad2 (Fig. 7 C) or Smad3 (Fig. 7 D) enhanced these typical TGF-β–induced morphological changes; however, the effect of Smad3 was stronger than that of Smad2, which is consistent with the milder effects of Smad2 versus Smad3 on TGF-β–induced inhibition of lipid accumulation (Fig. 5 C). Expression of Smad2SSMS conferred a morphology intermediate between the vector control and Smad2 overexpressing cells (Fig. 7 E). In contrast, Smad3SSVS expression counteracted the cell shape changes induced by TGF-β and allowed a level of lipid accumulation (Fig. 7 F), which approached that of control cells in the absence of TGF-β (Fig. 7 A). In the absence of TGF-β, the morphology of the different Smad-expressing cell lines was similar to each other, except that the Smad3-expressing cells were somewhat more spindly and densely packed (data not shown), which is consistent with a constitutive level of TGF-β signaling. These results identify Smad3 as a major regulator of adipogenic differentiation and of TGF-β–mediated inhibition of adipogenic conversion and growth stimulation. The Smad2 effects appear to be more complex and may reflect its involvement in only some TGF-β effects, yet suggest that Smad2 is also an important regulator of normal adipocyte differentiation.

Overexpression of Smad6 or Smad7 Blocks Adipogenesis and Enhances TGF-β–induced Growth and Inhibition of Differentiation

In contrast to the roles of Smad2 and Smad3 as TGF-β signaling effectors, Smad6 and Smad7 inhibit signaling by TGF-β family members. We hypothesized that the overex-
pression of these proteins might result in a more complete blockade of TGF-β signaling than expression of dominant negative Smad2 or 3 mutants expressed alone, or of dnTβRII. Furthermore, the downregulation of both Smad6 and Smad7 during adipocyte differentiation (Fig. 2) suggested a function for these Smads in the differentiation process. Therefore, we evaluated the consequences of stable overexpression of these two inhibitory Smads. Retroviral expression of Smad6 exceeded by far the expression level of Smad7 (Fig. 8A). Expression of the viral mRNAs for these Smads was much higher than the corresponding endogenous Smad transcripts (data not shown).

These cells were cultured under differentiation conditions, in the presence or absence of TGF-β, to assess the effects of Smad6 or Smad7 on adipogenic conversion, and on the ability of TGF-β to block differentiation. Expression of either Smad protein resulted in a profound blockade of lipid accumulation (Fig. 8B). Despite its lower expression level (Fig. 8A), the differentiation blockade induced by Smad7 was greater than that induced by Smad6. In the presence of TGF-β, this inhibition was even more complete, and no adipocytes could be found in Smad7 overexpressing cell cultures treated with TGF-β. These effects of Smad6 and Smad7 on adipose conversion were
also apparent in the analysis of adipocyte marker expression (Fig. 9 A). While C/EBPβ levels were not strongly affected, Smad6 or Smad7 overexpression increased the levels of C/EBPδ, which is normally downregulated during differentiation. These cells also showed strongly reduced PPARγ, C/EBPs, aP2, and adipin mRNAs, and a moderately reduced A D D-1 mRNA level. In the presence of TGF-β, all the TGF-β-induced changes in mRNA expression were enhanced by overexpression of Smad6 or Smad7.

We next tested the effect of Smad6 or Smad7 overexpression on cell proliferation in the absence or presence of TGF-β. Smad6 or Smad7 overexpression both greatly potentiated TGF-β-induced growth stimulation (Fig. 9 B) to a similar magnitude as Smad3 overexpression (Fig. 6 B). However, in contrast to the effect of Smad3 overexpression, the basal growth rate in the absence of added TGF-β was unchanged. Therefore, we conclude that Smad6 or Smad7 expression cooperates with TGF-β to enhance cell proliferation, but not in the same manner as Smad3.

The Smad6- or Smad7-expressing cells had an unusual morphology. When subconfluent, the cells were overall similar in size, but the Smad6 and Smad7 cells had a more cuboidal appearance and smoother edges, and seemed more contact-inhibited than control cells (Fig. 10 A). After reaching confluence under conditions that normally result in adipocyte differentiation, Smad6 and especially Smad7-overexpressing cells became very large and flat, in contrast to the compact piles of rounded, lipid-filled cells in control cultures (Fig. 10 B). The Smad7-overexpressing cells were generally larger and flatter than the Smad6-expressing cells, and had a higher incidence of giant cells, which were about fivefold larger than the surrounding cells (Fig. 10 D). The few adipocytes that did appear in the Smad6 or Smad7 cell cultures were very small in comparison to control adipocytes, and did not accumulate much lipid (Fig. 10 B, arrow). In the presence of TGF-β, all cell lines had a similar morphology, with the exception of the Smad6 or Smad7 cell cultures, which contained a few of the remnant larger cells (Fig. 10 C), and appeared larger overall.

To identify the domain of Smad7 that is required for its effects on adipogenesis, we evaluated the effects of expression of two different Smad7 mutants. The Smad7ΔC mutant has a 19–amino acid deletion at the COOH terminus, a mutation which abrogates the ability of Smad7 to block TGF-β receptor signaling (Hayashi et al., 1997). Conversely, expression of only the C-domain of Smad7, i.e., the Smad7C protein, is sufficient to block TGF-β receptor signaling similarly to full-length Smad7 (Souchelnytskyi et al., 1998). We stably expressed these mutant Smad7 proteins in 3T3-F442A cells, at levels similar to wild-type Smad7 (Fig. 11 A). The Smad7ΔC expressing cells accumulated lipid similarly as the vector control cells, whereas lipid accumulation was blocked in the Smad7C expressing cells (Fig. 11 B). Differentiation, as assessed by expression of PPARγ mRNA, also indicated that Smad7C, but not Smad7ΔC, decreased differentiation (Fig. 11 C). Staining of cells expressing Smad7C, but not Smad7ΔC, also revealed that Smad7C, but not Smad7ΔC, cooperated with TGF-β in blocking differentiation (Fig. 11 B and C). Smad7C, but not Smad7ΔC, also synergized with TGF-β in stimulating DNA synthesis (Fig. 11 D). Finally, the phenotype of the Smad7C cells resembled that of cells expressing wild-type Smad7, whereas Smad7ΔC expressing cells resembled vector control cells (Fig. 11 E). While Smad7C was qualitatively identical to wild-type Smad7 in our assays, it was quantitatively a weaker effector in comparison to full-length Smad7.

Our results indicate that Smad6 and Smad7 enhance, rather than inhibit, the effects of TGF-β signaling on adipogenic differentiation and cell proliferation. The C-domain of Smad7, which has been shown to be required for inhibition of TGF-β signaling in other experimental systems, is necessary and sufficient for its effects on adipocytic differentiation in 3T3-F442A cells.

**Discussion**

The ability of TGF-β and TGF-β–related factors to regulate mesenchymal differentiation is well documented. Nevertheless, little is known about the role of endogenous signaling by TGF-β, or its related factors, or the Smads, in cell differentiation. In this study, we have investigated the
functions of endogenous TGF-β and Smad signaling in adipocyte differentiation, using a well-known model system for adipocyte differentiation. While exogenous TGF-β is known to inhibit adipocyte differentiation, TGF-β also has been shown to be endogenously produced by adipocytes. Furthermore, preadipocytes secrete and activate TGF-β, whereas mature adipocytes do not (Rahimi et al., 1998). These observations suggested a role for autocrine TGF-β signaling in adipocyte differentiation. We now show that endogenous TGF-β receptor signaling is regulated during adipocyte differentiation, that autocrine TGF-β signaling modulates differentiation, and that Smad2 and Smad3 have distinct roles in the differentiation of these cells. Finally, our results indicate that Smad6 and Smad7 act as negative regulators of adipocyte differentiation, and enhance, rather than inhibit, TGF-β signaling in these cells.

**Figure 11.** Effect of expression of Smad7ΔC versus Smad7C on differentiation, proliferation, and cell morphology. (A) Expression of Smad7C and Smad7ΔC in stable 3T3-L1 cell lines, as determined by Flag immunoprecipitation and Western blotting. The expression of wild-type Smad7 in the corresponding stable 3T3-L1 cell line is shown alongside to enable a comparison of the expression levels. (B) Lipid accumulation in Smad7ΔC- and Smad7C-expressing cells. Vector control and Smad7ΔC- or Smad7C-expressing cell lines were grown as in Fig. 8B, and stained with Oil Red O. (C) Northern analysis of PPARγ expression in Smad7ΔC- and Smad7C-expressing cells. Total RNA was isolated on the days indicated, blotted, and hybridized as in Fig. 8B. (D) Cell proliferation in the absence or presence of TGF-β. Cells were untreated, or TGF-β was added to 5 ng/ml, and [3H]thymidine incorporation was measured. Values are expressed as fold induction relative to the untreated vector control. (E) Cell morphology of Smad7ΔC- and Smad7C-expressing cells at 4 d after confluence in differentiation medium without (top row) or with (bottom row) 1 ng/ml TGF-β.

**Regulation and the Role of TGF-β Receptor Signaling in Adipogenesis**

To characterize the potential role of autocrine TGF-β in adipose differentiation, we assessed the availability of receptors for TGF-β binding during differentiation. We found that the cell-surface expression of the TGF-β receptors is strongly downregulated during adipose differentiation. Our results are in accordance with the strong decrease in ligand binding during differentiation of primary rat adipocytes (Serrero and Mills, 1991) and of H1B-1B brown adipocytes (data not shown), but contrast with the apparent lack of repression of TGF-β binding in differentiating 3T3-L1 preadipocytes (Ignnotz and Massagué, 1985; data not shown). Since TGF-β inhibits adipocyte differentiation, the repression of TGF-β receptor availability may enable the cells to withdraw from the autocrine, differentiation inhibitory activity of TGF-β. This downregulation
may also explain why cells become refractory to the differentiation-inhibitory effect of TGF-β once differentiation has commenced. Accordingly, TGF-β did not inhibit 3T3-F442A adipose conversion at 3–4 d after confluence, by which time there is a significant loss of TGF-β binding (data not shown).

The downregulation of cell-surface TGF-β receptors in 3T3-F442A adipocytes is reminiscent of observations in other types of mesenchymal differentiation. Differentiation of myoblasts into myocytes is accompanied by a strong decrease in TGF-β binding sites at the cell surface (Hu and Olson, 1990), whereas the availability of type II but not type I TGF-β receptors is downregulated during osteoblastic differentiation (Centrella et al., 1995). These observations suggest that autocrine TGF-β signaling controls mesenchymal cell differentiation, and that these cells alter their autocrine TGF-β response during differentiation to allow for efficient maturation. Other mechanisms in addition to receptor availability may also be involved; e.g., 3T3-L1 adipocytes differentiate without repressing TGF-β binding (Ignotz and Massagué, 1985), but differentiation is accompanied by a block in activation of autocrine latent TGF-β (Rahimi et al., 1998).

The differentiation-inhibiting role of autocrine TGF-β in adipogenesis was confirmed in cells expressing a dominant negative version of the type II TGF-β receptor. Even though we did not obtain high levels of dnTβRII expression, the cells showed a decreased response to TGF-β. The dnTβRII cells had accelerated differentiation, suggesting that autocrine TGF-β responsiveness regulates adipose conversion. These observations suggest that decreased receptor availability during adipogenesis allows these cells to escape the autocrine differentiation-inhibitory and growth-promoting roles of TGF-β. The observation that retrovirally expressed cell-surface wild-type or dnTβRII were not decreased during differentiation, whereas endogenous cell-surface TβRII was decreased without a decrease in mRNA levels, suggests that the differentiation-dependent decrease in receptor availability results from translational repression.

**Regulation and the Roles of Smad2 and Smad3 in Adipogenesis**

Smad2 and Smad3 are both activated in response to TGF-β and act, in cooperation with Smad4, as effectors of the TGF-β response. All three Smads are expressed in 3T3-F442A cells, and their mRNA levels do not change significantly during differentiation. Whether Smad protein levels or their activation are altered during differentiation is currently unknown and awaits the availability of better antibodies. Our data also show that TGF-β represses Smad3 but not Smad2 mRNA expression, and that this TGF-β-induced repression decreases with differentiation, which is consistent with the downregulation of the cell-surface TGF-β receptors. Whether cells alter Smad expression and activation as a mechanism to regulate TGF-β responsiveness during differentiation is currently unclear. However, a recent report suggests differential expression of Smads at different stages during maturation of chondrocytes (Sakou et al., 1999).

To characterize the roles of Smad2 and Smad3, we generated 3T3-F442A cells that stably overexpress either wild-type or dominant negative versions of Smad2 or Smad3. We assessed the effect of these manipulations on preadipocyte growth and differentiation, and the TGF-β response. This study revealed different roles for Smad2 and Smad3. Overexpression of Smad3 decreased differentiation and increased proliferation in the absence or presence of TGF-β, suggesting that Smad3 overexpression mimicked and enhanced the TGF-β response. Conversely, dominant negative interference with Smad3 signaling enhanced the rate and extent of differentiation and inhibited cell proliferation. These results suggest that Smad3 mediates the differentiation-inhibiting and proliferative responses to TGF-β.

In contrast to Smad3, alterations of Smad2 function did not affect cell proliferation, in the absence or presence of TGF-β. However, increased Smad2 levels inhibited differentiation, albeit to a milder extent than Smad3, and enhanced the differentiation inhibitory response to TGF-β. Remarkably, expression of dominant negative Smad2 had a similar, but smaller, effect on differentiation as wild-type Smad2. These observations were not peculiar to the ΔSSXS mutations, since cells stably expressing dominant negative versions of Smad2 or Smad3 with the last three serines mutated to alanines (Macias-Silva et al., 1996; Liu et al., 1997), behaved identically to the ΔSSXS mutants (data not shown). In principle, this effect could be explained by a possible weak residual activity of the mutated Smad2ΔSSSM S or Smad2SA; however, this seems unlikely since we did not observe such behavior with the corresponding mutants of Smad3. Since Smad2 is also activated by activin, dominant negative interference with Smad2 signaling may primarily inhibit activin signaling, and this effect could explain the ability of Smad2ΔSSSM S to inhibit differentiation and to enhance the TGF-β response. Whether activin signaling contributes to adipogenesis remains to be explored since nothing is yet known about the function of activin in adipocyte differentiation.

**Regulation and the Roles of Smad6 and Smad7 in Adipogenesis**

While Smad2 and Smad3 are effectors of the TGF-β response, Smad6 and Smad7 have been shown to act as inhibitors of TGF-β responses. In contrast to Smad2 and Smad3, Smad6 and Smad7 mRNA expression is strongly repressed as adipogenesis proceeds. Since TGF-β can induce Smad6 and Smad7 expression (Nakao et al., 1997; Afrahtke et al., 1998; Chen et al., 1999), it is possible that the loss of Smad6 and Smad7 expression results from the downregulation of cell-surface receptors for TGF-β and, consequently, a lack of autocrine TGF-β stimulation.

The downregulation of Smad6 and Smad7 suggested that these Smads normally exert an inhibitory effect on adipocyte differentiation, which is suppressed by the cells to allow full differentiation. Alternatively, the inhibitory effect of Smad6 and Smad7 on the TGF-β response could suggest that increased Smad6 or Smad7 expression would favor adipogenic differentiation. Remarkably, Smad6 or Smad7 overexpression blocked adipogenesis and enhanced the inhibitory effect of TGF-β on differentiation. In addition, Smad6 or Smad7 overexpression also enhanced the...
TGFB-β-induced stimulation of cell proliferation, without changing the growth rate in the absence of exogenous TGFB-β. This effect contrasts with the growth stimulatory effect of Smad3 overexpression, which enhances cell proliferation both in the absence or presence of TGFB-β. While the activities of Smad6 and Smad7 appeared qualitatively the same, Smad7 was more potent than Smad6, in spite of its lower level of overexpression.

The mechanisms by which Smad6 and Smad7 block adipocyte differentiation and enhance the TGFB-β response are unclear. However, we determined that the C-domain of Smad7 is necessary and sufficient for these effects in 3T3-F442A cells. This region is also required for the inhibitory effect of Smad7 on TGFB-β receptor signaling (Hayashi et al., 1997; Souchelnytskyi et al., 1998), suggesting that the mechanism could be receptor-mediated. Since the inhibitory effects of Smad6 and Smad7 on ligand-induced responses are not restricted to TGFB-β, it is conceivable that the observed phenotype results from inhibition of autocrine responsiveness to another TGFB-β family member, such as BMP or activin. A accordingly, BMPs have been shown to regulate adipogenic differentiation: BMP-7 stimulates (A sahina et al., 1996) whereas BMP-2 has been reported to stimulate or inhibit adipogenic differentiation (Ahrens et al., 1993; Wang et al., 1993; Gimble et al., 1995). The differentiation stage and relative expression of the two BMP type I receptors, BMP-RIA and -RIB, may determine the nature of the autocrine response. Interference with BMP-RIA signaling can inhibit adipocyte conversion of mouse calvarial 2T3 cells, whereas a block in BMP-RIB signaling promotes adipocyte differentiation of these cells (Chen et al., 1998). Whether the differentiation and proliferation phenotypes of our Smad6 or Smad7 overexpressing cells can be explained through inhibition of BMP signaling remains to be investigated.

The molecular basis for the remarkable phenotype of the large cells in the Smad6 or Smad7 overexpressing cell lines also remains to be determined. It is conceivable that this phenotype results from an indiscriminate block in autocrine responsiveness to the different TGFB-β-related factors by Smad6 or Smad7. This blockage may disable the mesenchymal differentiation program, which would be consistent with the ability of Smad7 to block mesoderm differentiation and to induce formation of neural tissue in Xenopus (Bhushan et al., 1998; Casellas and Hemmati-Brivanlou, 1998). Similar data have been presented for Smad6 (Nakayama et al., 1998). However, the phenotype of our Smad6 and Smad7 stable cell lines does not suggest acquisition of a neuronal phenotype, and indeed, development of neural tissue in Xenopus is believed to be a default developmental response. Thus, Smad6 or 7 overexpression may prevent differentiation along the mesenchymal lineage.

In summary, our results suggest that autocrine TGFB-β regulates the rate of adipose conversion, and that cells reduce their autocrine response to TGFB-β by repressing the availability of the TGFB-β receptors as they differentiate. The effects of TGFB-β on preadipocyte differentiation are mediated by Smad2 and Smad3, which have distinct functions in differentiation. The mechanisms by which Smad2 and Smad3 block differentiation may be related to their well-known ability to interact with and modify the activity of transcription factors. Whether these Smads target the transcription factors that drive adipose differentiation is currently under investigation. Since TGFB-β did not affect the induction of C/EBPβ and -α, but blocked the induction of A D D-1, PPA R γ, and C/EBPα, Smad2 or Smad3 may exert their effects at some point upstream of A D D-1 and PPA R γ induction. The function of Smad6 and Smad7 may be to block premature differentiation (akin to the function of autocrine TGFB-β production), possibly by blocking several TGFB-β family signaling pathways. The current observations provide a basis for the investigation of the molecular mechanisms whereby these Smads regulate adipocyte differentiation.

We thank the following investigators for plasmids and cell lines: K. Easley (Harvard Medical School, Boston, MA), H. Green, S. Itoh, S. M K night, K. Miyazono, G. Nolan, B. Spiegelman, P. ten Dijke, and X.-F. Wang (Duke University Medical School, Durham, NC). We also thank Y. Zhang for providing the Smad3SS5V5 mutant construct, and X.-H. Feng for rounding up many other constructs from outside investigators. We are grateful to E. Filavaroff and M. Baudou (both from University of California, San Francisco, San Francisco, CA) for help with obtaining the retroviral packaging cell lines, and to T. Alliston, J. Q. Ling, and H. F. Chan for helpful discussions and encouragement.

This research was supported by a grant from the Arthritis Foundation and the National Institutes of Health grants P50-DE10306 (Project IV) and P60-DE1305 (Project III) to R. Derynck, and postdoctoral fellowships from the American Cancer Society and the American Heart Association to L. Choy.

Submitted: 21 September 1999
R evised: 17 February 2000
A ccepted: 14 March 2000

References

Afrakhte, M., A. Morén, S. Jossan, S. Itoh, K. Sampath, B. Westermarck, C.H. Ahrens, M., T. Ankenbauer, D. Schröder, A. Hollnagel, H. Mayer, and G. Gross. 1993. Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T1/2. cells induces differentiation into distinct mesenchymal cell lineages. DNA Cell Biol. 12:871–880.

Ahn, J. A., T.-K. Sampath, and P. V. Haushka. 1996. Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Exp Cell Res. 222:38–47.

Aubel, D., F. Bréant, S. M. Knight, D. M. O’neill, J. G. Seidman, J. A. Smith, and K. Struhl. 1994. Current Protocols of Molecular Biology. John Wiley & Sons, New York.

Ballock, R. T., A. Heydemann, L. M. Wakefield, K. C. Flanders, A. B. Roberts, and M. B. Sporn. 1993. TGFB-1 prevents hypertrophy of epithelial chondrocytes: regulation of gene expression for cartilage matrix proteins and metalloproteases. Dev. Biol. 158:414–429.

Beauchamp, R. D., H. M. Sheng, C. C. Bascom, D. A. Miller, R. M. Lyons, G. Torre-Arriola, and H. L. Moses. 1992. Phenotypic alterations in fibroblasts and fibrosarcoma cells that overexpress latent transforming growth factor-β. Endocrinology. 130:2476–2486.

Bhushan, A., Y. Chen, and W. Vale. 1998. Smad7 inhibits mesoderm formation and promotes neural cell fate in Xenopus embryos. Dev. Biol. 200:260–268.

Bertell, R., T. A. Owen, R. Ignatz, G. S. Stain, and J. L. Stein. 1994. TGFB-1 promotes the down-regulation of type I procollagen, fibronectin, and TGFB-1 gene expression associated with 3T3-L1 pre-adipocyte differentiation. J. Cell. Biochem. 54:256–263.

Casellas, R., and A. Hemmati-Brivanlou. 1998. Xenopus Smad7 inhibits both the activin and BMP pathways and acts as a neural inducer. Dev. Biol. 201:12–12.

Centrella, M., S. Cacangino, J. Kim, T. Pham, V. Rosen, J. Wozney, and T. M. Carthy. 1995. Independent changes in type I and type II receptors for transforming growth factor-β induced by bone morphogenetic protein 2: parallel expression of the osteoblast phenotype. Mol. Cell. Biol. 15:3273–3281.

Centrella, M., M. C. Horowitz, J. M. Wozney, and T. L. McCarthy. 1994. Transforming growth factor-β gene family members and bone. Endocrine Rev. 15: 27–39.

Chen, D., X. Ji, M. A. Harris, J. Q. Feng, G. Karsenty, A. J. Celeste, V. Rosen, G. R. Mundy, and S. E. Harris. 1998. Differential roles for bone morphoge-
nietic protein (BMP) receptor type IB and IA in differentiation and specifici-
cation of mesenchymal precursor cells to osteoblast and adipocyte lineages. J. Cell Biol. 142:295–305.

Chen, R.-H., and R. Derynck. 1994. Homomeric interactions between the type II TGF-β receptors. J. Biol. Chem. 269:22866–22874.

Chen, R.-H., and R. Derynck. 1993. Inactivation of the type II TGF-β receptor reveals two receptor pathways for the diverse TGF-β activities. Science. 260:1335–1338.

Chen, S.-J., W. Yuan, Y. Mori, A. Levenson, M. Trojanowska, and J. Varga. 1998. Stimulation of type I collagen transcription and its phosphorylation is required for nuclear accumulation and signaling. Cell. 87:1215–1224.

Masaavage, J. 1998. TGF-β signal transduction. Annu. Rev. Biochem. 67:753–789.

Masaavage, J., S. Cheifetz, T. Endo, and B. Nadal-Ginard. 1986. Type β transforming growth factor is an inhibitor of myogenic differentiation. Proc. Natl. Acad. Sci. USA. 83:8206–8210.

Miller, A.D., and G.J. Rosen. 1989. Improved retroviral vectors for gene transfer and expression. Biotechniques. 7:980–988.

Morgenstern, J.P., and H. Land. 1990. Advanced mammalian gene transfer: high titer retroviral vectors with multiple drug selection markers and a compatible helper-free packaging cell line. Nucleic Acids Res. 18:3567–3569.

Nakao, A., M. A. Frakenhe, A. Moren, T. Nakayama, J.L. Christian, R. Heuchel, S. Itoh, M. Kawabata, N.E. Heldin, C.H. Heldin, and P. ten Dijke. 1997. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signaling. Nature 389:631–635.

Nakayama, T., H. Gardner, L.K. Berg, and J.L. Christian. 1998. Smad6 functions as an intracellular antagonist of some TGF-β family members during Xenopus embryogenesis. Genes Cells. 3:387–394.

Olson, E.N., E. Sternberg, J.S. Hu, G. Spizz, and C. Wiltner. 1986. Regulation of myogenic differentiation by type β transforming growth factor. J. Cell Biol. 103:1799–1805.

Petruscheck, T., K. Rohrig, and H. Hauner. 1994. Transforming growth factor β1 TGF-β1 inhibits the differentiation of human adipocyte precursor cells in primary culture. Int. J. Obs. Relat. Endocr. 11:1835–1836.

Rahimi, N., E. Trembly, L. Maca, A. Roberts, and B. Elliott. 1998. A urocrine secretion of TGF-β1 and TGF-β2 by pre-adipocyes and adipocytes: a potent negative regulator of adipocyte differentiation and proliferation of mammary carcinoma cells. In Vitro Cell Dev. Biol. 34:412–420.

Sakou, T., T. Onishi, T. Yamamoto, T. Nagamine, T. Samath, and P. ten Dijke. 1999. Localization of Smads, the TGF-β family intracellular signaling components during endochondral ossification. J. Bone Miner. Res. 14:1145–1152.

Sambard, K.-T. Usyal, S.M. Wiebeck, M. Pandey, G.S. Hatiamislij, and D. J. Loskotusk. 1999. Tumor necrosis factor-α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc. Natl. Acad. Sci. USA. 96:6902–6907.

Samad, F., K. Yamamoto, M. Pandey, and D. J. Loskotusk. 1997. Elevated expression of transforming growth factor β1 in adipose tissue from obese mice. Int. J. Mol. Med. 3:37–42.

Serrero, G., and D. Mills. 1991. Decrease in transforming growth factor-β1 binding during differentiation of rat adipocyte precursors in primary culture. Cell Growth Differ. 2:171–179.

Slager, H.G., W. van Inzen, E. Freund, A. M.J. van den Eijken-van Raa, and C.L. Mummery. 1993. Transforming growth factor-β1 in the early mouse embryo: implications for the regulation of muscle formation and implantation. Dev. Genet. 14:212–224.

Souchetsytsky, S., T. Nakayama, A. Nakao, A. Moren, C.H. Heldin, J.L. Christian, and P. ten Dijke. 1998. Physical and functional interaction of murine and Xeno smad7 with bone morphogenetic protein receptors and transforming growth factor-β receptors. J. Biol. Chem. 273:25364–25370.

Sparks, R.L., and R.E. Scott. 1986. Transforming growth factor type β1 TGF-β1 protein in mouse fibroblasts and its effect on cell proliferation. Cancer Res. 46:329–334.

Stroschein, S.L., W. Wang, S. Zhou, Q. Zhou, and K. Luo. 1999. Negative-feedback control of transforming growth factor-α production in the 3T3-L1 adipocyte. J. Cell Biol. 142:295–305.

Macias-Silva, M.-S., A. Boobah, P. Hoodless, R. Pirrone, L. A. Tatsino, and J.L. Christian. 1996. A D-R2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell. 87:1215–1224.

Macias-Silva, M.-S., A. Boobah, P. Hoodless, R. Pirrone, L. A. Tatsino, and J.L. Christian. 1996. A D-R2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell. 87:1215–1224.
responses in endothelial cells. Proc. Natl. Acad. Sci. USA. 05:9506–9511.
Torti, F. M., B. Dieckmann, B. Beutler, A. Cerami, and G. M. Ringold. 1985. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science. 229:867–869.
Torti, F. M., S.V. Torti, J. W. Larrick, and G. M. Ringold. 1989. Modulation of adipocyte differentiation by tumor necrosis factor and transforming growth factor-β. J. Cell Biol. 108:1105–1113.
Wade, T. P., A. Kasid, C. A. Stein, R. V. LaRocca, E. R. Sargent, L. G. Gomella, C. E. Myers, and W. M. Linehan. 1992. Suramin interference with transforming growth factor-β inhibition of human renal cell carcinoma in culture. J. Surg. Res. 53:195–198.
Wang, E. A., D. J. Israel, S. Kelly, and D. P. Luxenberg. 1993. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors. 9:57–71.
W hitman, M. 1998. Smads and early developmental signaling by the TGF-β superfamily. Genes Dev. 12:2445–2462.
Wotton, D., R. S. Lo, S. Lee, and J. Massagué. 1999. A Smad transcriptional corepressor. Cell. 97:29–39.
Xing, H., J. P. Northrop, J. R., C. Grove, K. E. Kilpatrick, J. L. Su, and G. M. Ringold. 1997. TNF-α-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPAR-γ without effects on Pref-1 expression. Endocrinology. 138:2776–2783.
Zhang, Y., and R. Derynck. 1998. Smad3 and Smad4 cooperate with c-jun/c-Fos to mediate TGF-β-induced transcription. Nature. 394:909–913.